Neutralizing antibody responses against SarS-CoV-2 spike receptor-binding domain 13 months after the recovery from the disease
Keywords:
SARS-CoV-2, COVID-19, coronavirus, antibody responses, immunityAbstract
Background. Information regarding the kinetics and longevity of acquired immunity in recovered COVID-19 patients requires thorough analysis and documentation. This is an update to an ongoing monocentric pilot observational study, that longitudinally analyzed the presence of antibodies after SARS-CoV-2 infection. Study design. Antibody titers against nucleocapsid protein (NCP) of SARS-CoV-2 analyzed at 8 months was followed by adoption of a more specific immunoassay, anti-Spike-Receptor binding domain IgG CLIA for analysis at 12 and 13 months post infection.
Methods. MAGLUMI® SARS-CoV-2 S-RBD IgG Chemiluminescence immunoassay (CLIA) was adopted for measurement of antibody titres at 12 and 13 months after SARS-CoV-2 infection.
Results. 97% (34 out of 35) patients resulted positive for anti-SARS-CoV-2 RBD IgG at 12 and 13 months. Discussion and Conclusions. In areas with vaccine and resource scarcity, vaccination could be prioritized for those individuals who have never been infected or for the ones who have recovered but show the absence of protective antibodies.
References
1. Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22; 395(10224): 565-74. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30. PMID: 32007145; PMCID: PMC7159086.
290 P. Dehgani-Mobaraki et al.
2. Wu LP, Wang NC, Chang YH, et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007 Oct; 13(10): 1562-4. doi: 10.3201/eid1310.070576. PMID: 18258008; PMCID: PMC2851497.
3. Hall VJ, Foulkes S, Charlett A, et al. SARSCoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet 2021 Apr 17; 397(10283): 1459-69. doi: 10.1016/
S0140-6736(21)00675-9. Epub 2021 Apr 9. PMID: 33844963; PMCID: PMC8040523.
4. Matusali G, Colavita F, Lapa D, et al; Inmi Covid-Laboratory Team. SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus. Viruses. 2021 Apr 10; 13(4): 655. doi: 10.3390/v13040655. PMID:
33920222; PMCID: PMC8069482.
5. Dehgani-Mobaraki P, Kamber Zaidi A, Porreca
A, et. al. Antibody persistency and trend postSARS-CoV-2 infection at eight months. Ann Ig. 2021 Jun 11. doi: 10.7416/ai.2021.2455. Epub ahead of print. PMID: 34113953.
6. MAGLUMI® SARS-CoV-2 S-RBD IgG
(CLIA). 2021. Available on: https://www.finddx. org/product/maglumi-sars-cov-2-s-rbd-igg-clia/ [Last accessed: 2021, Jun 23].
7. Dispinseri S, Secchi M, Pirillo MF, et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat Commun 2021 May 11; 12(1): 2670. https://doi.org/10.1038/s41467-
021-22958-8. PMID: 33976165; PMCID:
PMC8113594.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.